Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment.
Clin Immunol
; 198: 31-38, 2019 01.
Article
en En
| MEDLINE
| ID: mdl-30503407
ABSTRACT
In this study, we investigated whether plasma cytokine/chemokine levels could predict HBsAg loss or clinical relapse (CR) after stopping nucleos(t)ides analogue (NA) treatment. Theplasma cytokines/chemokines levels were measured at 0, 4, 8, 12, 24 and 48â¯weeks after NA discontinuation by using the enzyme-linked immunoassay (ELISA) kit. Cox regression analysis revealed that CXCL13 level at the end of treatment (EOT) was an independent predictor for CR (HR 0.26, pâ¯<â¯0.001) and HBsAg loss (HR 3.01, pâ¯=â¯0.008) after treatment cessation. Among the patients with EOT CXCL13 levelâ¯<â¯80â¯pg/ml, the cumulative incidences of CR and HBsAg loss were 65% and 0% at 4â¯years, respectively. As for the patients with EOT CXCL13 levelâ¯≥â¯1000â¯pg/ml, 47.5% cases had HBsAg loss. Our study showed that EOT CXCL13 level was associated with off-treatment response, which may be used to guide cessation of NA treatment in clinical practice.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Hepatitis B Crónica
/
Quimiocina CXCL13
/
Antígenos de Superficie de la Hepatitis B
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Clin Immunol
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2019
Tipo del documento:
Article
País de afiliación:
China